Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Ahead of World Diabetes Day, Doctors Without Borders/Médecins Sans Frontières (MSF) called for all insulin manufacturers to provide injection pen devices at $1 per pen.
在世界糖尿病日到來之前，無國界醫生組織呼籲所有胰島素製造商將注射筆設備的價格定爲每支1美元。
The humanitarian organization emphasized that this would help ensure access to life-saving treatment for millions in low- and middle-income countries, where many struggle to afford diabetes care.
這家人道主義組織強調，這將幫助確保低收入和中等收入國家數百萬人的生命救治，他們在糖尿病護理方面苦苦掙扎，難以負擔。
MSF highlighted that Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Sanofi SA (NASDAQ:SNY), which dominate the global insulin market, have the power to set high prices that restrict access.
無國界醫生指出，主導全球胰島素市場的禮來（紐交所：LLY）、諾和諾德（紐交所：NVO）和賽諾菲（納斯達克：SNY）有能力設定高價，從而限制獲取。
Also Read: Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
另請參閱：施貴寶斐德表現搶眼，市值增長近25%，但諾和諾德和禮來遭遇市場挫折
According to MSF, data published in JAMA Network Open shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
根據無國界醫生的數據，發表在《JAMA網絡開放》上的數據顯示，胰島素筆每個單位的生產成本低至0.94美元，仍然可以盈利，但目前價格遠遠高於這一數字。
For instance, a pen costs $1.99 in South Africa, $5.77 in India, $14.00 in the Philippines, and $90.69 in the U.S.
例如，在南非，一支筆的價格爲1.99美元，在印度爲5.77美元，在菲律賓爲14.00美元，而在美國爲90.69美元。
Dr. Helen Bygrave, an advisor for MSF's Access Campaign, underscored the disparity by recalling the initial intentions of the scientists who discovered insulin. "Over 100 years ago, they sold the patent for just $1 to ensure global access. Now, only about half of those who need insulin can access it," she said.
無國界醫生的獲取運動顧問海倫·拜格博士強調了差異，回憶起發現胰島素的科學家的初衷。"在100多年前，他們以僅1美元的價格出售專利，以確保全球獲取。現在，只有大約一半需要胰島素的人能夠獲取它，"她說。
She stated that the corporate control by Eli Lilly, Novo Nordisk, and Sanofi has led to a "double standard" that hinders equitable diabetes treatment.
她表示，禮來、諾和諾德和賽諾菲的公司控制導致了一個"雙重標準"，阻礙了公平的糖尿病治療。
In July, the FDA rejected Novo Nordisk's BLA filing for the once-weekly insulin icodec.
在七月，FDA拒絕了諾和諾德的每週一次胰島素icodec的BLA申請。
Insulin pens, known for their dosing accuracy and user-friendly design, have been preferred by 82% of surveyed diabetes patients due to their convenience and less invasive administration compared to vials and syringes.
胰島素筆因其劑量準確和易於使用的設計而受到82%受訪糖尿病患者的青睞，因爲與瓶和針筒相比，它們更便捷且侵入性更小。
Recently, Novo Nordisk decided to cease insulin pen production to prioritize its GLP-1 medications for diabetes and obesity, like Ozempic and Wegovy.
最近，諾和諾德決定停止胰島素筆的生產，以優先考慮其用於糖尿病和肥胖症的GLP-1藥物，如Ozempic和Wegovy。
This shift, motivated by profit margins in wealthier markets, could force many patients back to using syringes and vials.
這一轉變是由於在富裕市場的利潤空間，可能迫使許多患者重新使用針筒和瓶裝胰島素。
South Africa, which transitioned to insulin pens in its public sector in 2014, recently faced a shortage that led to rationing when Novo Nordisk paused the supply of human insulin pens to the government.
南非自2014年在其公共部門轉向使用胰島素筆後，最近面臨短缺，導致在諾和諾德暫停向政府供應人胰島素筆時實施配給。
- FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
- FDA局長卡利夫坦誠談特朗普的影響：『我們不知道會發生什麼』
Photo by towfiqu barbhuiya via unsplash
照片由towfiqu barbhuiya通過unsplash拍攝
譯文內容由第三人軟體翻譯。
